Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema.
Treatment with 17 alpha-methyltestosterone and with some synthetic androgens prevents attacks of hereditary angioedema (HAE). However, the potential hepatotoxicity of 17 alpha-alkylated androgens raises the problem of long-term prophylactic use of these agents. Therefore we compared the efficacy in preventing HAE attacks of 17 alpha-alkylated steroids (danazol and stanozolol) with non-17 alpha-alkylated derivatives (quinbolone, nandrolone decanoate and mesterolone). As the latter group proved ineffective, it seems that a drug's efficacy in preventing HAE attacks is connected to its 17 alpha-alkylation. Moreover, our long-term observations with the minimum effective dose of danazol seem to indicate the absence of important collateral effects.
D000328:Adult; D000730:Androstadienes / Q000008:administration & dosage; D000799:Angioedema / Q000188:drug therapy / Q000235:genetics*; D003174:Complement C1 Inactivator Proteins; D003181:Complement C4; D003613:Danazol / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008655:Mesterolone / Q000008:administration & dosage; D008875:Middle Aged; D009277:Nandrolone / Q000008:administration & dosage; D011245:Pregnadienes / Q000008:administration & dosage*; D013197:Stanozolol / Q000008:administration & dosage* / Q000627:therapeutic use
D000730:Androstadienes; D003174:Complement C1 Inactivator Proteins; D003181:Complement C4; D011245:Pregnadienes; D008655:Mesterolone; D013197:Stanozolol; D009277:Nandrolone; D003613:Danazol; C005620:quinbolone